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SHORT COMMUNICATION
Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid
(HDFA) in hepatocellular carcinoma
A. Zaniboni, E. Simoncini, P. Marpicati & G. Marini
lIIa Divisione di Medicina Generale, Servizio di Oncologia, Fondazione Beretta Spedali Civili, 25100 Brescia, Italy.
Nonresectable hepatocellular carcinoma (NHC) has a very
poor prognosis with virtually no patients (pts) surviving 5
years from diagnosis (Moertel, 1973).
Doxorubicin is one of the most active agents in the
treatment of NHC, with a median response rate of up to
25% (Friedman, 1983). However, a more recent study
reported a response rate of only 10% in 109 patients,
although 27% of symptomatic patients had an improvement
in performance status and symptom control (Sciarrino et al.,
1985). 5-Fluorouracil (5-FU) as a single agent has a quite
low activity in NHC with a median response rate of 20%
(range 0-50%) in three different studies (Cady et al., 1985);
nevertheless it is included in almost all the combination
regimens tested in NHC (Friedman, 1983; Cady et al., 1985).
Recent studies suggest that the therapeutic activity of 5-FU
may be enhanced by increasing endogenous reduced folate
pools in vivo (Rustum, 1985) and the combination of 5-FU
and high-dose folinic acid (HDFA) seems quite promising in
gastrointestinal malignancies (Machover et al., 1986). We
report here the results of a phase II study with 5-FU and
HDFA performed in an attempt to improve the results
obtained with 5-FU alone in NHC.
From January 1986 to March 1987 14 consecutive
previously untreated patients with histologically or cyto-
logically proven NHC were treated with the following
regimen: HDFA - 200mgm-2 by i.v. infusion over 2h
followed by 5-FU - 370mgm-2 by i.v. infusion over 15min
daily for 5 consecutive days repeated every 4 weeks. Patients
characteristics are outlined in Table I.
Eligibility requirements included an ECOG performance
status .3, WBC >4000mm 3, platelet > 100,000mm
serum creatinine <2mg%, bilirubin <2mg%, no prior
treatment and measurable disease. At the initiation of
treatment full blood count, HbsAg determination, chest X-
ray, liver CT scan and/or ultrasonography and alpha-
foetoprotein assay were performed.
Evaluation of response took place after at least two cycles
according to WHO criteria (WHO, 1979) while toxicity was
assessed according to Miller's score (Miller et al., 1981).
Response was assessed utilizing the same techniques (liver
CT and/or ultrasound, chest X-ray) performed before the
start of the study.
No response was seen in any of the 14 evaluable patients;
6 had stabilization of disease for a median duration of 82
days (range 70-128) while 8 progressed. Median survival was
Table I Patient characteristics
Total entered 14
Total evaluable 14
Sex
Male/female 12/2
Age (yrs)
Median: 47.3
Range: 39-68
ECOG performance status
Median: 2
Range: 1-3
HbsAg-positive 10/14
Concomitant liver cirrhosis 5/14
Distant metastases 4/14
Lung= 3
Nodes= 2
Soft tissues= 1
Alpha foetoprotein (IUmlP)
Median: 487
Range: 8-175,000
Histology
Well differentiated 12
Anaplastic 2
98 days (range 44-281) with no difference between patients
with stable or progressive disease. Treatment did not
influence AFP levels in any patient.
A total of 56 cycles was administered with a median of 4
cycles for each patient (range 2-9). Nausea and vomiting
were completely absent; three patients experienced grade II
diarrhoea, while two patients had grade III oral mucostitis.
One patients developed a partial alopecia; only one patient
had a grade II granulocytopenia. In this quite homogeneous
group of patients with NHC, the true response rate of
HDFA+5-FU is <20% at the 95% confidence interval (Lee
et al., 1979).
Although well tolerated, the combination of HDFA and
5-FU seems unable to produce better results than 5-FU
alone in NHC.
Efforts continue to seek ways to im'rove the outcome of
NHC and all patients with primary liver cancer must be
considered candidates for investigative protocols.
References
CADY, B., McDONALD, J.S. & GUNDERSON, L.L. (1985). Cancer of
the hepatobiliary system. In Cancer Principles and Practice of
Oncology, De Vita et al. (eds) p. 750. Lippincott: Philadelphia.
FRIEDMAN, M.A. (1983). Primary hepatocellular cancer. Present
results and future prospects. Int. J. Radiat. Oncol. Biol. Phys., 9,
1841.
LEE, Y.J., STAQUET, M. & SIMON, R. (1979). Two-stage plans for
patient accrual in phase II cancer clinical trials. Cancer Treat.
Rep., 63, 1721.
Correspondence: A. Zaniboni.
Received 6 August 1987; and in revised form, 4 November 1987.
MACHOVER, D., GOLDSCHMIDT, E. & CHOLLET, P. (1986).
Treatment of advanced colorectal and gastric adenocarcinomas
with 5-FU and high dose folinic acid. J. Clin. Oncol., 4, 685.
MILLER, A.B., HOOGSTRATEN, B., STAGNET, M. & WINKLER, A.
(1981). Reporting results ofcancer treatment. Cancer, 47, 207.
MOERTEL, C.G. (1973). The liver. In Cancer Medicine, Holland, J.F.
& Frei, E., III. (eds) p. 1541. Lea & Febiger: Philadelphia.
RUSTUM, Y.M. (1985). Selective modulation of 5-Fluorouracil action
in patients with colorectal carcinoma. Chemioterapia, 4, 377.
SCIARRINO, E., SIMONETTI, R.G., LE MOLI, S. & 6 others (1985).
Adriamycin treatment for hepatocellular carcinoma experience
with 109 patients. Cancer, 56, 2751.
WHO (1979). Handbook for reporting results of cancer treatment.
WHO offset publication No. 48. WHO: Geneva.